Donafenib Monotherapy for Previously Treated Metastatic Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
The investigators do the clinical trial (patients with metastatic nasopharyngeal carcinoma
treated with donafenib after failure of standard therapy) to assess safety and efficacy of
donafenib in patients with metastatic nasopharyngeal carcinoma, progressing after all
approved standard therapies.